Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).

被引：0
|
作者：
Stilgenbauer, S [1 ]
Winkler, D [1 ]
Kröber, A [1 ]
Kienle, D [1 ]
Hallek, M [1 ]
Hensel, M [1 ]
Lengfelder, E [1 ]
Trümper, L [1 ]
Dreger, P [1 ]
Jäger, U [1 ]
Döhner, H [1 ]
机构：
[1] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
478
引用
收藏
页码：140A / 140A
页数：1
相关论文
共 50 条
  • [21] Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)
    Sayala, HA
    Moreton, P
    Jones, RA
    Rawstron, AC
    O'Connor, SJ
    Evans, P
    Carter, A
    Dearden, C
    Matutes, E
    Pettitt, AR
    Kennedy, DB
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 3 - 3
  • [22] In vivo 'purging' of residual disease in CLL with Campath-1H
    Dyer, MJS
    Kelsey, SM
    Mackay, HJ
    Emmett, E
    Thornton, P
    Hale, G
    Waldmann, H
    Newland, AC
    Catovsky, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) : 669 - 672
  • [23] Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)
    Fink, Anna
    Busch, Raymonde
    Pflug, Natali
    Boettcher, Sebastian
    Winkler, Dirk
    Buehler, Andreas
    Ritgen, Matthias
    Fischer, Kirsten
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Mendila, Myriam
    Wenger, Michael K.
    Doehner, Hartmut
    Kneba, Michael
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2011, 118 (21) : 446 - 447
  • [24] Sequential subcutaneous administration of Campath-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP).
    Montillo, M
    Tedeschi, A
    Cafro, AM
    Rossi, V
    D'Avanzo, G
    Pungolino, E
    Cairoli, R
    Oreste, P
    Veronese, S
    Brando, B
    Morra, E
    BLOOD, 2002, 100 (11) : 804A - 804A
  • [25] Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study
    Dyer, MJS
    Buckby, E
    Fermahan, P
    Walewska, R
    Kennedy, B
    BLOOD, 2005, 106 (11) : 830A - 830A
  • [26] Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis.
    Rai, KR
    Coutre, S
    Rizzieri, D
    Gribben, JG
    Flinn, I
    Rabinowe, S
    Keating, MJ
    BLOOD, 2001, 98 (11) : 365A - 365A
  • [27] Biological, and molecular characterization of lymphocytes in a refractory CLL responding to CAMPATH-1H treatment.
    Cortelezzi, A
    Barcellini, W
    Fracchiolla, NS
    Sarina, B
    Calori, R
    Bianchi, P
    Lambertenghi-Deliliers, G
    Zanella, A
    BLOOD, 1999, 94 (10) : 297B - 297B
  • [28] NCRN CLL207 study of alemtuzumab consolidation in CLL: report of the planned interim analysis
    Hillmen, P.
    Cohen, D.
    Gregory, W.
    Smith, A.
    Skinner, E.
    Critchley, A.
    Rawstron, A.
    Deardon, C.
    McCarthy, H.
    Follows, G.
    Fegan, C.
    Pocock, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 45 - 45
  • [29] Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Robrecht, Sandra
    Bahlo, Jasmin
    Al-Sawaf, Othman
    Langerbeins, Petra
    Heinz, Werner
    Vehling-Kaiser, Ursula
    Durig, Jan
    Tausch, Eugen
    Hensel, Manfred
    Fink, Anna-Maria
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara F.
    Hallek, Michael J.
    BLOOD, 2017, 130
  • [30] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
12345